Outcomes of first-line (1L) ipilimumab and nivolumab (IPI-NIVO) and subsequent therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).

被引：1
|
作者：
Gan, Chun Loo
Wells, J. Connor
Schmidt, Andrew Lachlan
Powles, Thomas
Tran, Ben
Meza, Luis A.
Labaki, Chris
Lee, Jae-Lyun
Wood, Lori
Shapiro, Julia
Ernst, D. Scott
Kapoor, Anil
Canil, Christina M.
Yuasa, Takeshi
McKay, Rana R.
Beuselinck, Benoit
Donskov, Frede
Dudani, Shaan
Choueiri, Toni K.
Heng, Daniel Yick Chin
机构：
[1] Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada
[2] Univ Calgary, Calgary, AB, Canada
[3] Cairns & Hinterland Hosp & Hlth Serv, Liz Plummer Canc Ctr, Cairns, Qld, Australia
[4] Queen Mary Univ London, Royal Free Natl Hlth Serv Trust, Canc Res UK Expt Canc Med Ctr, Barts Canc Inst, London, England
[5] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[6] City Hope Comprehens Canc Ctr, Duarte, CA USA
[7] Dana Farber Canc Inst Individuals, Boston, MA USA
[8] Asan Med Ctr, Seoul, South Korea
[9] Univ Ulsan, Coll Med, Seoul, South Korea
[10] Dalhousie Univ, Halifax, NS, Canada
[11] Cabrini Hlth, Melbourne, Vic, Australia
[12] London Hlth Sci Ctr, London Reg Canc Program, Dept Oncol, Div Med Oncol, London, ON, Canada
[13] Univ Western Ontario, London, ON, Canada
[14] St Josephs Healthcare, McMaster Inst Urol, Hamilton, ON, Canada
[15] Univ Ottawa, Ottawa Hosp, Ottawa, ON, Canada
[16] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
[17] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA
[18] Univ Ziekenhuizen, Leuven Canc Inst, Leuven, Belgium
[19] Aarhus Univ Hosp, Aarhus, Denmark
[20] Univ Ottawa, Ottawa Hosp Canc Ctr, Ottawa, ON, Canada
[21] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.4554
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4554
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Real world outcomes of first line (1L) nivolumab and ipilimumab (NIVO IPI) in metastatic renal cell carcinoma (mRCC): An update from the International mRCC Database Consortium (IMDC).
    Ferrier, Evan
    Lemelin, Audreylie
    Powles, Thomas
    Pal, Sumanta Kumar
    Ebrahimi, Hedyeh
    Agarwal, Neeraj
    Beuselinck, Benoit
    Bjarnason, Georg A.
    Wood, Lori
    Canil, Christina M.
    Saliby, Renee Maria
    de Velasco, Guillermo
    Mckay, Rana R.
    Tran, Ben
    Suarez, Cristina
    Templeton, Arnoud J.
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 395 - 395
  • [2] Characterizing progression to subsequent lines of therapy in metastatic renal cell carcinoma (mRCC) after nivolumab plus ipilimumab (Nivo plus Ipi): Results from the International mRCC Database Consortium (IMDC).
    Lemelin, Audreylie
    Takemura, Kosuke
    Ernst, Matthew Scott
    Wells, J. Connor
    Donskov, Frede
    Porta, Camillo
    de Velasco, Guillermo
    Davis, Ian D.
    Wood, Lori
    Pal, Sumanta Kumar
    Hansen, Aaron Richard
    Kollmannsberger, Christian K.
    Bjarnason, Georg A.
    Tran, Ben
    Li, Haoran
    Kanesvaran, Ravindran
    Powles, Thomas
    McKay, Rana R.
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] Outcomes of first-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).
    Gan, Chun Loo
    Dudani, Shaan
    Wells, Connor J.
    Schmidt, Andrew Lachlan
    Bakouny, Ziad
    Szabados, Bernadett
    Parnis, Francis
    Wong, Shirley
    Lee, Jae-Lyun
    de Velasco, Guillermo
    Pal, Sumanta K.
    Davis, Ian D.
    Kanesvaran, Ravindran
    Wood, Lori
    Kollmannsberger, Christian K.
    McKay, Rana R.
    Beuselinck, Benoit
    Donskov, Frede
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [4] Third line therapy in metastatic renal cell carcinoma (mRCC): results from the international mRCC database consortium (IMDC)
    Stukalina, Igor
    Wellsa, J. Connor
    Donskovb, Frede
    Rinic, Brian I.
    Leed, Jae-Lyun
    Bjarnasone, Georg A.
    Beuselinckf, Benoit
    Smoragiewicz, Martin
    Alvah, Ajjai Shivaram
    Srinivasi, Sandy
    Woodi, Lori
    Saleemk, Sadia
    Pal, Sumanta Kumar
    Yuasam, Takeshi
    Broomn, Reuben James
    Kanesvaran, Ravindran
    Bamiasp, Aristotelis
    Knoxq, Jennifer J.
    Henga, Daniel Y. C.
    Choueirir, Toni K.
    BJU INTERNATIONAL, 2015, 116 : 21 - 21
  • [5] Third-line therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC)
    Heng, Daniel Yick Chin
    Stukalin, Igor
    Wells, Connor
    Donskov, Frede
    Rini, Brian I.
    Lee, Jae-Lyun
    Bjarnason, Georg A.
    Beuselinck, Benoit
    Smoragiewicz, Martin
    Alva, Ajjai Shivaram
    Srinivas, Sandy
    Wood, Lori
    Brugarolas, James
    Pal, Sumanta Kumar
    Yuasa, Takeshi
    Broom, Reuben James
    Kanesvaran, Ravindran
    Bamias, Aristotelis
    Knox, Jennifer J.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [6] First-line (1L) immuno-oncology (10) combination therapies in metastatic renal-cell carcinoma (mRCC): Results from the international mRCC database consortium (IMDC).
    Dudani, Shaan
    Graham, Jeffrey
    Wells, Connor
    Bakouny, Ziad
    Pal, Sumanta K.
    Dizman, Nazli
    Donskov, Frede
    Porta, Camillo
    de Velasco, Guillermo
    Hansen, Aaron Richard
    Iafolla, Marco Adelmo James
    Beuselinck, Benoit
    Vaishampayan, Ulka N.
    Wood, Lori
    Liow, Elizabeth Chien Hern
    Yan, Flora
    Yuasa, Takeshi
    Bjarnason, Georg A.
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [7] Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC)
    Stukalin, Igor
    Wells, J. Connor
    Fraccon, Anna
    Pasini, Felice
    Porta, Camillo
    Lalani, Aly-Khan A.
    Srinivas, Sandy
    Bowman, I. Alex
    Brugarolas, James
    Lee, Jae-Lyun
    Donskov, Frede
    Beuselinck, Benoit
    Bamias, Aristotelis
    Rini, Brian, I
    Sim, Hao-Wen
    Agarwal, Neeraj
    Rha, Sun-Young
    Kanesvaran, Ravindran
    Choueiri, Toni K.
    Heng, Daniel Y. C.
    KIDNEY CANCER, 2018, 2 (01) : 31 - 36
  • [8] First-line mTOR inhibition in metastatic renal cell carcinoma (mRCC): An updated analysis from the International mRCC Database Consortium (IMDC).
    Harshman, Lauren Christine
    Kroeger, Nils
    Rha, Sun Young
    Donskov, Frede
    Wood, Lori
    Tantravahi, Srinivas Kiran
    Vaishampayan, Ulka N.
    Rini, Brian I.
    Knox, Jennifer J.
    North, Scott A.
    MacKenzie, Mary J.
    Yuasa, Takeshi
    Srinivas, Sandy
    Pal, Sumanta Kumar
    Heng, Daniel Yick Chin
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [9] Fourth-line targeted therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).
    Stukalin, Igor
    Wells, Connor
    Fraccon, Anna Paola
    Pasini, Felice
    Porta, Camillo
    Moreira, Raphael Brandao
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [10] Comparison of cabozantinib (CABO) versus sunitinib (SUN) following first-line (1L) nivolumab plus ipilimumab (NIVO plus IPI) for metastatic renal cell carcinoma (mRCC): A target trial emulation using real-world data from the International mRCC Database Consortium (IMDC)
    Lemelin, A.
    Takemura, K.
    Boyne, D. J.
    Warkentin, M. T.
    Brenner, D. R.
    Cheun, W. Y.
    Wells, J. C.
    Labaki, C.
    McGregor, B. A.
    Basappa, N. S.
    Meza, L. A.
    Pal, S. K.
    Beuselinck, B.
    Mckay, R. R.
    Szabados, B. E.
    Powles, T. B.
    Yuasa, T.
    Ludwig, L.
    Choueiri, T. K.
    Heng, D. Y. C.
    ANNALS OF ONCOLOGY, 2023, 34 : S1023 - S1024
12345